Premarket Trading Ideas:
BIG, FRO, DXLG, HRTX, GME, ULTA
Premarket Earning:
Bank of Nova Scotia ( BNS) is reporting for the quarter ending April 30, 2015. The bank (foreign) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.14. This value represents a 11.63% decrease compared to the same quarter last year. The last two quarters BNS had negative earnings surprises; the latest report they missed by -5.22%.
Big Lots, Inc. ( BIG) is reporting for the quarter ending April 30, 2015. The discount retail company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.59. This value represents a 18.00% increase compared to the same quarter last year. BIG missed the consensus earnings per share in the 4th calendar quarter of 2014 by -20%. The "days to cover" for this stock exceeds 11 days.
Genesco Inc. ( GCO ) is reporting for the quarter ending April 30, 2015. The retail (shoe) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.68. This value represents a 16.05% decrease compared to the same quarter last year.
Frontline Ltd. ( FRO) is reporting for the quarter ending March 31, 2015. The shipping company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.06. This value represents a 50.00% increase compared to the same quarter last year. The last two quarters FRO had negative earnings surprises; the latest report they missed by -1200%.
Graham Corporation ( GHM ) is reporting for the quarter ending March 31, 2015. The machinery company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.32. This value represents a 39.13% increase compared to the same quarter last year.
Destination XL Group, Inc. ( DXLG ) is reporting for the quarter ending April 30, 2015. The retail (shoe) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.06. This value represents a 50.00% decrease compared to the same quarter last year. The "days to cover" for this stock exceeds 26 days.
Economic Calendar:
| Session | Time | Currency | Event | Impact | Actual | Forecast | Prev. | |||
|---|---|---|---|---|---|---|---|---|---|---|
| 2:00 | EUR | German Retail Sales | med | 1 | -1.4 | |||||
| 2:00 | EUR | German Retail Sales | med | 2.5 | 3.5 | |||||
| 2:45 | EUR | French PPI | med | 0.1 | ||||||
| 2:45 | EUR | French Consumer Spending | low | 0.4 | -0.6 | |||||
| 2:45 | EUR | French Consumer Spending | low | 2.4 | 2.1 | |||||
| 2:45 | EUR | French PPI | med | -2.2 | ||||||
| 4:00 | EUR | M3 Money Supply (sa) | med | 4.5 | 4.1 | |||||
| 4:00 | EUR | M3 Money Supply (sa) | med | 4.9 | 4.6 | |||||
| 8:30 | USD | Core PCE Price Index (2nd Est.) | med | 0.9 | 0.9 | |||||
| 8:30 | USD | GDP Annualised (2nd Est.) | high | -0.8 | 0.2 | |||||
| 8:30 | USD | GDP Price Index (2nd Est.) | low | -0.1 | -0.1 | |||||
| 9:45 | USD | Chicago PMI | med | 53 | 52.3 | |||||
| 10:00 | USD | Univ of Mich Sent. (final) | med | 89.5 | 88.6 | |||||
After Hour News that matters:
Heron Therapeutics, Inc. (Nasdaq: HRTX) 39.8% HIGHER; announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Companys 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Stemline Therapeutics (NASDAQ: STML) 13.3% HIGHER; announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). These results demonstrate an acceptable safety profile, with no cumulative side effects observed after multiple cycles of SL-401 administered at dose levels up to 12 ug/kg/day. Three out of five BPDCN patients treated at the 12 ug/kg/day dose achieved major responses to date, including complete responses (CRs). Stemline intends to continue to enroll BPDCN patients in this ongoing pivotal trial at the 12 ug/kg/day dose level.
GameStop (NYSE: GME) 4.1% HIGHER; reported Q1 EPS of $0.68, $0.09 better than the analyst estimate of $0.59. Revenue for the quarter came in at $2.06 billion versus the consensus estimate of $2.01 billion. Same store sales increase 8.6% driven by 10% growth in new software sales. GameStop sees Q2 2015 EPS of $0.21-$0.25. GameStop raises FY2015 EPS to $3.63-$3.83, versus prior guidance of $3.60-$3.80 and the consensus of $3.83.
MagnaChip (NYSE: MX) 3.3% HIGHER; reported Q1 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $179.55 million.
Infoblox (NYSE: BLOX) 2.6% HIGHER; reported Q3 EPS of $0.12, $0.05 better than the analyst estimate of $0.07. Revenue for the quarter came in at $78.1 million versus the consensus estimate of $75.25 million. Infoblox sees Q4 2015 EPS of $0.09-$0.10, versus the consensus of $0.09. Infoblox sees Q4 2015 revenue of $79-81 million, versus the consensus of $78.4 million.
Ulta Salon (NASDAQ: ULTA) 1.8% HIGHER; reported Q1 EPS of $1.04, $0.11 better than the analyst estimate of $0.93. Revenue for the quarter came in at $868.1 million versus the consensus estimate of $845.83 million. Comparable sales (sales for stores open at least 14 months and e-commerce sales) increased 11.4% compared to an increase of 8.7% in the first quarter of fiscal 2014. Ulta Salon sees Q2 2015 EPS of $1.07-$1.12, versus the consensus of $1.09. Ulta Salon sees Q2 2015 revenue of $854-868 million, versus the consensus of $859.25 million. Comparable sales for the second quarter of 2015, including e-commerce sales, are expected to increase 7% to 9%.
Deckers Outdoor (NASDAQ: DECK) 1.2% LOWER; reported Q4 EPS of $0.04, $0.04 better than the analyst estimate of $0.00. Revenue for the quarter came in at $340.6 million versus the consensus estimate of $321.59 million. Deckers Outdoor sees FY2016 EPS of $5.60, versus the consensus of $5.05. Deckers Outdoor sees FY2016 revenue of $2.01 billion, versus the consensus of $1.95 billion. Deckers Outdoor sees Q1 2016 EPS of ($1.52), versus the consensus of ($1.17)
Boot Barn Holdings (NYSE: BOOT) 1.1% HIGHER; reported Q4 EPS of $0.17, versus $0.18 reported last year. Revenue for the quarter came in at $103.3 million, versus $88.5 million reported last year. Same store sales, which include e-commerce sales, increased 7.0%. Boot Barn Holdings sees FY2016 EPS of $0.81-$0.86.
Cellectis (NASDAQ: CLLS) 0.9% LOWER; gives ups some intra-day gains as todays' takeover rumors are being highly questioned.
No comments:
Post a Comment